KR20220054025A - A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising fermented-benicasa hispida extract - Google Patents
A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising fermented-benicasa hispida extract Download PDFInfo
- Publication number
- KR20220054025A KR20220054025A KR1020200138474A KR20200138474A KR20220054025A KR 20220054025 A KR20220054025 A KR 20220054025A KR 1020200138474 A KR1020200138474 A KR 1020200138474A KR 20200138474 A KR20200138474 A KR 20200138474A KR 20220054025 A KR20220054025 A KR 20220054025A
- Authority
- KR
- South Korea
- Prior art keywords
- bacillus
- extract
- metabolic syndrome
- fermented
- copper
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 47
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 23
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims description 33
- 239000000598 endocrine disruptor Substances 0.000 title description 14
- 231100000049 endocrine disruptor Toxicity 0.000 title description 14
- 201000010099 disease Diseases 0.000 title description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 12
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 229940088597 hormone Drugs 0.000 claims description 34
- 239000005556 hormone Substances 0.000 claims description 34
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 30
- 229910052802 copper Inorganic materials 0.000 claims description 30
- 239000010949 copper Substances 0.000 claims description 30
- 230000007613 environmental effect Effects 0.000 claims description 28
- 244000063299 Bacillus subtilis Species 0.000 claims description 13
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 13
- 230000037356 lipid metabolism Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 230000005856 abnormality Effects 0.000 claims description 9
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical group C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 claims description 8
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 7
- 241000192132 Leuconostoc Species 0.000 claims description 7
- 241000193744 Bacillus amyloliquefaciens Species 0.000 claims description 5
- 241000194107 Bacillus megaterium Species 0.000 claims description 5
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 claims description 5
- 241001123633 Galactomyces Species 0.000 claims description 5
- 241000235070 Saccharomyces Species 0.000 claims description 5
- 229930185605 Bisphenol Natural products 0.000 claims description 3
- 241001627205 Leuconostoc sp. Species 0.000 claims description 3
- 125000005498 phthalate group Chemical class 0.000 claims description 3
- 235000011274 Benincasa cerifera Nutrition 0.000 abstract description 5
- 241001464410 Benincasa hispida Species 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 31
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 16
- 230000036541 health Effects 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 14
- 239000003642 reactive oxygen metabolite Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000013376 functional food Nutrition 0.000 description 11
- 230000006372 lipid accumulation Effects 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 210000001789 adipocyte Anatomy 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- PXKLMJQFEQBVLD-UHFFFAOYSA-N bisphenol F Chemical compound C1=CC(O)=CC=C1CC1=CC=C(O)C=C1 PXKLMJQFEQBVLD-UHFFFAOYSA-N 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 229960004308 acetylcysteine Drugs 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 244000036905 Benincasa cerifera Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 244000168141 Geotrichum candidum Species 0.000 description 4
- 235000017388 Geotrichum candidum Nutrition 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- -1 parabens Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 244000045195 Cicer arietinum Species 0.000 description 3
- 235000010523 Cicer arietinum Nutrition 0.000 description 3
- 239000004803 Di-2ethylhexylphthalate Substances 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BKUSIKGSPSFQAC-RRKCRQDMSA-N 2'-deoxyinosine-5'-diphosphate Chemical compound O1[C@H](CO[P@@](O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(NC=NC2=O)=C2N=C1 BKUSIKGSPSFQAC-RRKCRQDMSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- IRIAEXORFWYRCZ-UHFFFAOYSA-N Butylbenzyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IRIAEXORFWYRCZ-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 235000015001 Cucumis melo var inodorus Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102100035474 DNA polymerase kappa Human genes 0.000 description 1
- 101710108091 DNA polymerase kappa Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 208000008892 Lipoid Proteinosis of Urbach and Wiethe Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000219098 Parthenocissus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000235088 Saccharomyces sp. Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 1
- HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 231100000507 endocrine disrupting Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 201000005604 lipoid proteinosis Diseases 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 동과 발효 추출물을 유효성분으로 포함하는 대사증후군 개선용 조성물에 관한 것으로, 의약품 및 식품 등 다양한 용도로서 활용 가능하다.The present invention relates to a composition for improving metabolic syndrome comprising a copper ferment extract as an active ingredient, and can be used for various purposes such as medicines and food.
대사증후군(Metabolic Syndrome)은 고중성지방혈증, 고혈압, 당대사 이상, 혈액응고 이상 및 비만과 같은 위험 인자가 함께 나타나는 증후군을 지칭한다. Metabolic syndrome refers to a syndrome in which risk factors such as hypertriglyceridemia, hypertension, glucose metabolism abnormality, blood coagulation abnormality, and obesity appear together.
대사증후군의 증상 자체는 치명적이지 않지만 당뇨병이나 허혈성 심혈관계 질환과 같은 심각한 질병으로 발전할 소인이 있기 때문에 현대인의 건강을 크게 위협하고 있다.The symptoms of metabolic syndrome itself are not fatal, but since they have a predisposition to develop into serious diseases such as diabetes or ischemic cardiovascular disease, they greatly threaten the health of modern people.
과거에는 원인이 밝혀지지 않아 X증후군(Syndrome X)을 비롯한 여러 종류의 이름으로 불렸으나, 세계보건기구와 미국 국립보건연구원의 심-폐-혈액 연구소(NHLBI)가 제정한 성인 치료프로그램 Ⅲ(Adult Treatment Program Ⅲ : ATP Ⅲ)을 통해 대사증후군 또는 인슐린저항성증후군(Insulin resistance syndrome)이라 공식 명명되었다.In the past, the cause was unknown, so it was called by various names including Syndrome X. Treatment Program Ⅲ: ATP Ⅲ) was officially named metabolic syndrome or insulin resistance syndrome.
미국 NCEP(National Cholesterol Education Program)의 기준에 따르면, ① 허리둘레가 남자 40 인치(102 cm), 여자 35 인치(88 cm) 이상인 복부 비만, ② 중성지방(triglycerides) 150 mg/dL 이상, ③ HDL 콜레스테롤이 남자 40 mg/dL, 여자 50 mg/dL 이하, ④ 혈압 130/85 mmHg 이상, ⑤ 공복혈당(fasting glucose)이 110 mg/dL 이상 등의 다섯 가지 위험인자 중 한 환자가 세 개 이상을 나타낼 경우 대사증후군으로 판정하게 된다. According to the criteria of the National Cholesterol Education Program (NCEP) in the United States, ① abdominal obesity with a waist circumference of 40 inches (102 cm) for men and 35 inches (88 cm) for women, ② triglycerides 150 mg/dL or more, ③ HDL One of the five risk factors:
대사증후군의 원인으로는 인슐린 저항성이 가장 먼저 지적된 바 있다. Insulin resistance was first pointed out as a cause of metabolic syndrome.
혈당을 낮추기 위해 과량 분비된 인슐린이 혈당을 정상으로 조절하지 못하고 혈관세포 증식을 유도해 혈관 벽을 두껍게 하거나, 신장에서 나트륨의 재흡수를 촉진해 혈압을 높이거나, 지방분해를 촉진하여 혈액 내 중성지방을 높이는 동시에 고밀도 콜레스테롤을 낮추며 내장에 지방성분의 저장을 촉진시키는 등의 총체적인 작용으로 고혈압, 고지혈증, 복부 비만 등 대사 증후군을 유발하는 것으로 알려져 있다.Insulin, which is secreted excessively to lower blood sugar, fails to regulate blood sugar to normal, and induces vascular cell proliferation to thicken blood vessel walls, increases blood pressure by promoting sodium reabsorption in the kidney, or promotes lipolysis to neutralize blood It is known to cause metabolic syndrome such as high blood pressure, hyperlipidemia, and abdominal obesity with a holistic action such as raising fat while lowering high-density cholesterol and promoting the storage of fat components in the intestines.
한편, 환경호르몬은 학술용어로 환경성 내분비계 교란물질(endocrine disruptors)이라고 하는데, 환경으로 방출된 유해한 화학물질이 생체 내에 유입되어 호르몬 작용을 방해하거나 교란시키는 물질을 총칭한다.On the other hand, endocrine disruptors are a scientific term for endocrine disruptors, and it is a generic term for substances that interfere with or disrupt the action of hormones by introducing harmful chemicals released into the environment into the living body.
환경호르몬은 화학구조가 생체 호르몬과 비슷하여 몸속에서 마치 천연 호르몬인 것처럼 작용하는 경우가 많으며, 이와 같은 '모방(mimic)'을 통해 진짜 호르몬처럼 몸속의 세포 물질과 결합하여 비정상적인 생리작용을 한다. Environmental hormones often act as if they were natural hormones in the body because their chemical structure is similar to that of living hormones.
환경호르몬으로 현재까지 약 87,000 여종이 알려져 있고, 이 중 인체에 독성을 보이는 환경호르몬은 약 67종이며, 대표적 맹독성 환경호르몬 물질로는 다이옥신류, 프탈레이트 가소제류, 비스페놀 등이 있다.About 87,000 environmental hormones are known so far, and about 67 environmental hormones are toxic to the human body.
환경호르몬은 우리 몸의 지방조직 등에 침투한 뒤 잔류성 유기화학물질을 서서히 방출하면서 인슐린 저항성을 유발하므로, 이를 통해 지질대사이상 등의 대사증후군이 야기될 수 있다.Since environmental hormones induce insulin resistance by slowly releasing residual organic chemicals after penetrating into the adipose tissue of our body, metabolic syndrome such as abnormal lipid metabolism can be caused.
이에 따라 최근 내분비 교란물질에 의해 유발되는 질환에 대한 관심이 증가되고 있으며, 이를 개선하기 위한 다양한 연구가 진행되고 있다. Accordingly, interest in diseases caused by endocrine disruptors has recently increased, and various studies are being conducted to improve them.
본 발명자들은 동과 발효 추출물이 내분비 교란물질에 의해 유발되는 지질대사이상을 효과적으로 완화시키고 이로 인해 유발되는 대사증후군을 억제할 수 있음을 확인함으로써 본 발명을 완성하였다.The present inventors have completed the present invention by confirming that the fermented copper extract can effectively alleviate lipid metabolism abnormalities induced by endocrine disruptors and suppress metabolic syndrome induced thereby.
본 발명은 전술한 종래 기술의 문제점을 해결하기 위한 것으로, 본 발명의 목적은 생체 안전성이 우수한 천연 식물 유래의 기능성 식의약품을 제공하는 것이다.The present invention is to solve the problems of the prior art, and an object of the present invention is to provide a functional food product derived from a natural plant having excellent biosafety.
본 발명의 일 측면에 따르면, 동과 발효 추출물을 유효성분으로 포함하는 대사증후군 예방 또는 개선용 식품 조성물이 제공된다.According to one aspect of the present invention, there is provided a food composition for preventing or improving metabolic syndrome comprising a copper ferment extract as an active ingredient.
일 실시예에 있어서, 상기 대사증후군은 환경호르몬 유발 지질대사이상일 수 있다.In one embodiment, the metabolic syndrome may be an environmental hormone-induced lipid metabolism abnormality.
일 실시예에 있어서, 상기 환경호르몬은 비스페놀류, 파라벤류, 또는 프탈레이트류일 수 있다.In one embodiment, the environmental hormone may be bisphenols, parabens, or phthalates.
일 실시예에 있어서, 상기 동과 발효 추출물은 사카로마이세스 속(Saccharomyces spp.), 갈락토마이세스 속(Galactomyces spp.), 바실러스 속(bacillus spp.), 및 류코노스톡 속(Leuconostoc spp.)으로 이루어진 군에서 하나 이상 선택된 균주를 발효시켜 수득한 것일 수 있다.In one embodiment, the copper ferment extract is Saccharomyces genus ( Saccharomyces spp. ), Galactomyces spp. , Bacillus spp. ), and Leuconostoc spp . . ) may be obtained by fermenting one or more strains selected from the group consisting of.
일 실시예에 있어서, 상기 바실러스 속 균주는 바실러스 메가테리(Bacillus megaterium), 바실러스 아밀로리퀴페시언스(Bacillus amyloliquefaciens), 바실러스 서브틸리스(Bacillus subtilis)로 이루어진 군에서 하나 이상 선택될 수 있다.In one embodiment, the Bacillus sp. strain is Bacillus megaterium ( Bacillus megaterium ), Bacillus amyloliquefaciens ( Bacillus amyloliquefaciens ), Bacillus subtilis ( Bacillus subtilis ) One or more may be selected from the group consisting of.
일 실시예에 있어서, 상기 바실러스 속 균주는 미국 국립생물공학정보센터(NCBI)에 등록된 Bacillus subtilis CJH 101(MW063656) 이고, 상기 류코노스톡 속 균주는 미국 국립생물공학정보센터에 등록된 Leuconostoc mesenterodies CJH 205(MW079917)일 수 있다.In one embodiment, the Bacillus sp. strain is Bacillus subtilis CJH 101 (MW063656) registered with the National Center for Biotechnology Information (NCBI), and the Leuconostoc sp. strain is Leuconostoc mesenterodies registered with the National Center for Biotechnology Information. CJH 205 (MW079917).
본 발명의 다른 측면에 따르면, 동과 발효 추출물을 유효성분으로 포함하는 대사증후군의 예방 또는 치료용 약학적 조성물이 제공된다.According to another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating metabolic syndrome comprising a copper ferment extract as an active ingredient.
일 실시예에 있어서, 상기 대사증후군은 환경호르몬 유발 지질대사이상일 수 있다.In one embodiment, the metabolic syndrome may be an environmental hormone-induced lipid metabolism abnormality.
본 발명의 일 측면에 따른 조성물은 천연 발효 추출물을 유효성분으로 포함하여 생체 안전성이 우수할 뿐만 아니라 내분비 교란물질에 의한 지질대사이상을 개선함으로써 건강기능식품뿐만 아니라 이로 인해 유발되는 질환의 치료 용도로서 유용하게 활용할 수 있다.The composition according to one aspect of the present invention contains a natural fermented extract as an active ingredient and has excellent biosafety as well as a health functional food by improving lipid metabolism abnormality caused by endocrine disrupting substances, as well as for the treatment of diseases caused by this. It can be useful.
본 발명의 효과는 상기한 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.It should be understood that the effects of the present invention are not limited to the above-described effects, and include all effects that can be inferred from the configuration of the invention described in the detailed description or claims of the present invention.
도 1은 본 발명의 일 실시예에 따른 동과 발효 추출물의 세포 독성을 평가한 결과이다.
도 2는 대조군(MDI) 및 비스페놀 A, 동과 발효 추출물(HR1901-FRm-SC-W) 처리량을 달리한 실험군(좌측)의 지질축적량과 해당 결과를 그래프(우측)로 도시한 것이다.
도 3은 대조군(MDI) 및 비스페놀 A, 동과 발효 추출물(HR1901-FRm-SC-W) 처리량을 달리한 실험군(좌측)의 활성산소종 생성량과 해당 결과를 그래프(우측)로 도시한 것이다.1 is a result of evaluating the cytotoxicity of a fermented copper extract according to an embodiment of the present invention.
Figure 2 is a graph (right) showing the lipid accumulation amount and the corresponding results of the control group (MDI) and the experimental group (left) in which bisphenol A, copper ferment extract (HR1901-FRm-SC-W) treatment amount was different.
Figure 3 is a graph (right) showing the production amount of reactive oxygen species and the corresponding result of the control group (MDI) and the experimental group (left) in which bisphenol A, copper ferment extract (HR1901-FRm-SC-W) treatment amount was different.
본 명세서에서 사용되는 용어는 본 발명에서의 기능을 고려하면서 가능한 현재 널리 사용되는 일반적인 용어들을 선택하였으나, 이는 당 분야에 종사하는 기술자의 의도 또는 판례, 새로운 기술의 출현 등에 따라 달라질 수 있다. The terms used in this specification have been selected as currently widely used general terms as possible while considering the functions in the present invention, but these may vary depending on the intention or precedent of a person skilled in the art, the emergence of new technology, and the like.
또한, 특정한 경우는 출원인이 임의로 선정한 용어도 있으며, 이 경우 해당되는 발명의 설명 부분에서 상세히 그 의미를 기재할 것이다. 따라서 본 발명에서 사용되는 용어는 단순한 용어의 명칭이 아닌, 그 용어가 가지는 의미와 본 발명의 전반에 걸친 내용을 토대로 정의되어야 한다.In addition, in a specific case, there is a term arbitrarily selected by the applicant, and in this case, the meaning will be described in detail in the description of the corresponding invention. Therefore, the term used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, rather than the name of a simple term.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다. Unless defined otherwise, all terms used herein, including technical and scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Terms such as those defined in a commonly used dictionary should be interpreted as having a meaning consistent with the meaning in the context of the related art, and should not be interpreted in an ideal or excessively formal meaning unless explicitly defined in the present application. does not
수치 범위는 상기 범위에 정의된 수치를 포함한다. 본 명세서에 걸쳐 주어진 모든 최대의 수치 제한은 낮은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 낮은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 최소의 수치 제한은 더 높은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 높은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 수치 제한은 더 좁은 수치 제한이 명확히 쓰여져 있는 것처럼, 더 넓은 수치 범위 내의 더 좋은 모든 수치 범위를 포함할 것이다.Numerical ranges are inclusive of the values defined in that range. Every maximum numerical limitation given throughout this specification includes all lower numerical limitations as if the lower numerical limitation were expressly written. Every minimum numerical limitation given throughout this specification includes all higher numerical limitations as if the higher numerical limitation were expressly written. Any numerical limitation given throughout this specification shall include all numerical ranges within the broader numerical range, as if the narrower numerical limitation were expressly written down.
이하, 본 발명의 실시예를 상세히 기술하나, 하기 실시예에 의해 본 발명이 한정되지 아니함은 자명하다.Hereinafter, examples of the present invention will be described in detail, but it is obvious that the present invention is not limited by the following examples.
본 발명의 일 측면에 따르면, 동과 발효 추출물을 유효성분으로 포함하는 대사증후군 예방 또는 개선용 식품 조성물이 제공된다.According to one aspect of the present invention, there is provided a food composition for preventing or improving metabolic syndrome comprising a copper ferment extract as an active ingredient.
상기 “동과(winter melon)”는 박과의 한해살이 덩굴성 식물로 동아 또는 동화라고도 불리우며, 학명은 Benincasa hispida, Benincasa cerifera, Benincasa cerifera Savi 등이다.The “winter melon” is an annual creeper plant of the Cucurbitaceae family, also called Donga or Donghwa, and its scientific names are Benincasa hispida , Benincasa cerifera , Benincasa cerifera Savi and the like.
상기 동과는 열대 아시아산으로 중국을 통하여 우리나라에 전래되어 재배되기 시작한 것으로 알려져 있다. It is known that the copper fruit is from tropical Asia and was introduced to Korea through China and started to be cultivated.
상기 동과는 식용 또는 약용하여 왔고, 과거에는 동화선, 동화누르미, 동화적, 동화돈채 등 다양한 조리법으로 식용한 것으로 보고되고 있다.Donggwa has been edible or medicinal, and it has been reported that it was eaten in various recipes such as Donghwaseon, Donghwanurmi, Donghwahwa, and Donghwadonchae in the past.
생활비결서에 따르면 동과 즙액을 밤마다 얼굴에 바르고 자면 얼굴이 백옥처럼 희고 맑게 되므로 피부 미백에 탁월하다고 하였고, 검은 피부색을 바꾸는 비법이라 하였으며, 동과씨는 기미를 없애는 효능이 우수하다고 알려진 바 있다.According to the secret book for living, it is said that it is excellent for skin whitening because the face becomes as white and clear as white jade when sleeping with the extract of copper fruit applied to the face every night. there is.
그러나, 상기 동과의 환경호르몬 유발 질환 또는 관련 작용 기전은 현재까지 알려진 바 없으며, 본 발명자들은 비스페놀 A와 같은 환경호르몬뿐만 아니라, 그 유사체인 비스페놀 S, 비스페놀 F가 오비소겐(obesogen)으로써 이상지질대사를 유도함을 확인하고, 상기 동과가 환경호르몬으로 유도된 이상지질대사를 효과적으로 억제할 수 있음을 규명하였다.However, the endocrine disruptor-induced disease or related mechanism of action is not known to date, and the present inventors found that not only environmental hormones such as bisphenol A, but also its analogs, bisphenol S and bisphenol F, are abnormal lipids as obesogens. It was confirmed that the metabolism was induced, and it was confirmed that the Donggwa can effectively inhibit abnormal lipid metabolism induced by environmental hormones.
상기 대사증후군은 당뇨, 비만, 인슐린 저항성, 지방간, 고지혈증, 동맥경화 또는 이들의 합병증 등 사망의 위험인자들이 함께 존재하는 상태를 의미하며, 구체적으로 환경호르몬에 의해 유발되는 지질대사이상일 수 있다.The metabolic syndrome refers to a state in which risk factors for death such as diabetes, obesity, insulin resistance, fatty liver, hyperlipidemia, arteriosclerosis, or complications thereof exist together, and specifically may be abnormal lipid metabolism induced by environmental hormones.
상기 환경호르몬으로 널리 알려진 내분비 교란물질은 정상적인 체내 호르몬으로 작용하거나 기능을 방해하는 화학 물질일 수 있고, 상기 교란물질은 인공적으로 합성되어 사용되며, 일상생활 속에서 쉽게 노출될 수 있다.The endocrine disruptor, which is widely known as the environmental hormone, may be a chemical substance that acts as a normal body hormone or interferes with the function, and the disruptor is artificially synthesized and used, and may be easily exposed in daily life.
상기 내분비계 교란물질은 체내로 흡수되어 번식, 발달, 대사 및 면역과 관련된 정상적인 호르몬의 혼란을 유발할 수 있고, 호르몬의 합성, 저장, 분비, 수송, 결합 및 대사를 방해함으로써 다양한 질병을 유발할 수 있다.The endocrine disruptors may be absorbed into the body and cause disruption of normal hormones related to reproduction, development, metabolism and immunity, and may cause various diseases by interfering with the synthesis, storage, secretion, transport, binding and metabolism of hormones. .
상기 환경호르몬은 비만에 영향을 미치는 환경호르몬이라는 의미의 오비소겐(obesogen)이라는 단어가 적용될 수 있고, 구체적으로, 비스페놀류(BPA, BPF, BPS), 파라벤류(메틸파라벤, 에틸파라벤, 프로필파라벤, 부틸파라벤), 프탈레이트류(DEHP, DBP, BBP, DEP, DNOP, DIDP, DINP) 일 수 있다.As the environmental hormone, the word obesogen, meaning an environmental hormone that affects obesity, may be applied, and specifically, bisphenols (BPA, BPF, BPS), parabens (methylparaben, ethylparaben, propylparaben) , butylparaben), and phthalates (DEHP, DBP, BBP, DEP, DNOP, DIDP, DINP).
상기 “지질대사(Lipid metabolism)”는 콜레스테롤 대사 또는 중성지질 대사를 포함할 수 있으나, 이에 제한되는 것은 아니다.The “lipid metabolism” may include, but is not limited to, cholesterol metabolism or triglyceride metabolism.
상기 "콜레스테롤"은 동물세포의 세포막을 구성하는 데 필요한 기본 물질로, 식물에서는 합성되지 않고 동물에서만 합성된다. 상기 콜레스테롤은 여러 생물학적 스테로이드 물질의 전구체(precursor) 역할을 하므로 생체 내에 필수적이다.The "cholesterol" is a basic substance necessary to construct the cell membrane of animal cells, and is synthesized only in animals, not in plants. The cholesterol serves as a precursor of several biological steroid substances and is therefore essential in the living body.
상기 콜레스테롤은 식이로부터의 외인성 콜레스테롤과 체내에서 합성되는 내인성 콜레스테롤로부터 공급되며, 간에서 최종 대사산물인 담즙산으로 변하고, 장을 통해 배설될 수 있다. The cholesterol is supplied from exogenous cholesterol from the diet and endogenous cholesterol synthesized in the body, converted into bile acid, which is a final metabolite, in the liver, and can be excreted through the intestine.
상기 콜레스테롤의 수준이 체내에서 일정하게 유지되지 못하고, 세포에 의해 원활히 이용되지 못하는 경우 콜레스테롤은 체내에 축적되고, 죽상동맥경화증이나 관상동맥질환과 같은 여러가지 심혈관 질환의 일차적인 원인이 될 수 있다.When the level of cholesterol is not kept constant in the body and is not used smoothly by cells, cholesterol accumulates in the body and may be the primary cause of various cardiovascular diseases such as atherosclerosis or coronary artery disease.
상기 "중성지질"은 물에 녹지 않는 지방을 의미하며, 콜레스테릴 에스테르와 트리글리세라이드를 포함할 수 있다. The "neutral lipid" refers to a fat that does not dissolve in water, and may include cholesteryl esters and triglycerides.
상기 중성지방은 물에 용해되지 않으므로 혈액 속에서 단독으로 존재할 수 없어 운반체인 지단백이 필수적이다.Since the triglyceride is not soluble in water, it cannot exist alone in the blood, so lipoprotein as a carrier is essential.
체내 지방은 콜레스테롤과 중성지방으로 구성되고, 상기 중성지방은 LDL, 즉 나쁜 콜레스테롤의 생성을 돕고 좋은 콜레스테롤인 HDL의 분해를 촉진할 수 있다.Body fat is composed of cholesterol and triglycerides, and the triglycerides can help produce LDL, that is, bad cholesterol, and promote decomposition of HDL, which is good cholesterol.
상기 지질대사이상은 상기 지질이 생성 및 축적되는 대사과정이 적절히 조절되지 않아 체내에 지질이 축적되거나, 비만, 당뇨병, 고콜레스테롤증, 고중성지질혈증, 저지질증, 지방단백질증 또는 동맥경화 등의 질병을 야기할 수 있다.The lipid metabolism abnormality is the accumulation of lipids in the body because the metabolic process in which the lipids are produced and accumulated is not properly regulated, or obesity, diabetes, high cholesterol, hypertriglyceridemia, hypolipidemia, lipoproteinosis or arteriosclerosis, etc. can cause disease.
상기 “발효”는 미생물이 자신이 가지고 있는 효소를 이용해 유기물을 분해시키는 과정을 의미한다. 미생물을 통한 발효과정을 거친 원료는 발효 전보다 최소 2배에서 최대 수 십배의 활성이 증대되거나 기타 유효 성분의 함량이 현저히 변화될 수 있다.The “fermentation” refers to a process in which microorganisms decompose organic matter using their own enzymes. Raw materials that have been fermented through microorganisms may have at least two to ten times greater activity than before fermentation, or the content of other active ingredients may be significantly changed.
상기 발효를 거친 대사물질은 각종 아미노산, 유기산, 항산화 물질을 함유할 수 있으며, 발효 과정에 의해 입자가 작아지고 독성이 분해되어 흡수율이 증진될 수 있으므로, 그로 인한 기능성이 개선될 수 있다.The fermented metabolites may contain various amino acids, organic acids, and antioxidants, and by the fermentation process, the particles become smaller and the toxicity is decomposed to improve absorption, thereby improving functionality.
상기 “발효 추출물”은 천연 원료를 파쇄 등의 가공공정을 거치거나, 천연원료를 건조한 후 가수하여 발효 균주를 접종하고 발효시켜 제조할 수 있다.The “fermented extract” may be prepared by inoculating and fermenting a fermented strain by processing natural raw materials such as crushing, or by drying and then hydrolyzing natural raw materials.
상기 동과 발효 추출물은 효모(yeast)를 발효시켜 수득한 것일 수 있다.The copper fermented extract may be obtained by fermenting yeast.
상기 “효모(yeast)”는 곰팡이나 버섯 무리이지만 균사가 없고, 광합성능이나 운동성도 가지지 않는 단세포 생물을 총칭하는 것으로, 술이나 빵 등 식품의 발효에 널리 사용된다. The “yeast” is a group of fungi or mushrooms, but is a generic term for single-celled organisms that do not have mycelium and do not have photosynthetic performance or motility, and are widely used for fermentation of foods such as alcohol and bread.
구체적으로, 상기 효모는 사카로마이세스 속(Saccharomyces spp.) 또는 갈락토마이세스 속(Galactomyces spp.)일 수 있다.Specifically, the yeast may be of the genus Saccharomyces spp. or Galactomyces spp .
상기 사카로마이세스 속 균주는 사카로미세스 세레비시아(Saccharomyces cerevisiae), 사카로미세스 보우라디(Saccharomyces boulardii) 또는 사카로미세스 엘립소이드(Saccharomyces ellipsoids)일 수 있으나, 바람직하게는 사카로미세스 세레비지에(Saccharomyces cerevisiae)일 수 있다.The Saccharomyces sp. strain may be Saccharomyces cerevisiae , Saccharomyces boulardii , or Saccharomyces ellipsoids , but preferably Saccharomyces cerevisiae. It may be Saccharomyces cerevisiae .
상기 갈락토마이세스 속(Galactomyces spp.) 균주는 누룩으로 발효시키는 천연 효모 중 하나로, 바람직하게는 갈락토마이세스 지오트리쿰(Galactomyces geotrichum)일 수 있다.The genus Galactomyces ( Galactomyces spp. ) The strain is one of the natural yeast fermented with yeast, preferably Galactomyces geotrichum ( Galactomyces geotrichum ) It may be.
한편, 상기 동과 발효 추출물은 바실러스 속(bacillus spp.) 균주를 발효시켜 수득한 것일 수 있다.On the other hand, the copper fermented extract may be obtained by fermenting the Bacillus spp .
상기 바실러스 속(bacillus spp.) 균주는 막대 모양의 그람 양성균 세균의 총칭으로, 후벽균류의 한 종류이며, 바실러스 메가테리(Bacillus megaterium), 바실러스 아밀로리퀴페시언스(Bacillus amyloliquefaciens), 바실러스 서브틸리스(Bacillus subtilis)로 이루어진 군에서 하나 이상 선택될 수 있으나, 이에 제한되는 것은 아니다.The genus Bacillus ( bacillus spp. ) The strain is a generic term for rod-shaped Gram-positive bacteria, and is a kind of sclerotiae fungus, Bacillus megaterium ), Bacillus amyloliquefaciens ), Bacillus subtilis ( Bacillus subtilis ) One or more may be selected from the group consisting of, but is not limited thereto.
일 실시예에서, 상기 바실러스 속 균주는 미국 국립생물공학정보센터(NCBI)에 등록된 Bacillus subtilis CJH 101(MW063656) 이고, 상기 류코노스톡 속 균주는 미국 국립생물공학정보센터에 등록된 Leuconostoc mesenterodies CJH 205(MW079917)일 수 있다.In one embodiment, the Bacillus sp. strain is Bacillus subtilis CJH 101 (MW063656) registered with the National Center for Biotechnology Information (NCBI), and the Leuconostoc sp. strain is Leuconostoc mesenterodies CJH registered with the National Center for Biotechnology Information. 205 (MW079917).
본 발명자는 상기 발효 균주에서 가장 활성이 우수한 균주를 분리하고, 상기 균주를 미국 국립생물공학정보센터에 기탁하였다.The present inventor isolates the most active strain from the fermented strain, and deposited the strain in the US National Center for Biotechnology Information.
상기 “유효성분으로 포함하는”은 투여하고자 하는 개체에 대한 치료적 또는 예방적 효과를 제공하기에 충분한 양을 포함하는 것을 의미하며, 상기 동과 발효 추출물은 생체 안전성이 우수하므로 당업자가 양적 상한을 적절히 조정할 수 있다.The "comprising as an active ingredient" means including an amount sufficient to provide a therapeutic or prophylactic effect on the subject to be administered, and since the copper ferment extract is excellent in biosafety, those skilled in the art can determine the upper limit of the quantitative can be adjusted appropriately.
상기 “추출물”은 용매와 추출 원료를 특정 조건 하에서 접촉시킴으로써 추출 원료에 함유된 유효성분이 전이된 용매를 지칭하는 것으로, 천연물로부터 원료에 함유된 성분을 분리해낸 물질이라면, 추출 방법이나 성분의 종류와 무관하게 모두 포함할 수 있다. 예컨대, 상기 추출물은 물이나 유기용매를 이용하여 천연물로부터 용매에 용해되는 성분을 추출한 것, 천연물의 특정 성분, 예컨대 오일과 같은 특정 성분만을 추출하여 얻어진 것 등을 모두 포함할 수 있다.The “extract” refers to a solvent in which the active ingredient contained in the extraction raw material is transferred by contacting the solvent and the extraction raw material under specific conditions. They can all be included regardless. For example, the extract may include all of those obtained by extracting a component soluble in a solvent from a natural product using water or an organic solvent, and a specific component of a natural product, for example, extracting only a specific component such as oil.
상기 추출물은 동과를 건조 후 분말화하거나, 열수추출법, 에탄올 추출법 등 종래 알려진 다양한 추출법에 의해 수득할 수 있다.The extract can be obtained by drying and powdering copper fruit, or by various conventionally known extraction methods such as hot water extraction, ethanol extraction, and the like.
상기 추출물은 물, 알코올, 에틸아세테이트, 아세톤, 핵산, 디클로로메탄 또는 이들의 혼합 용매로 추출될 수 있으나, 이에 제한되는 것은 아니다.The extract may be extracted with water, alcohol, ethyl acetate, acetone, nucleic acid, dichloromethane, or a mixed solvent thereof, but is not limited thereto.
상기 원료에 포함된 유효성분은 용매의 극성에 따라 추출 비율이 상이해질 수 있으므로, 용매에 따른 생리 활성 물질의 선택성을 고려하여 달리할 수 있다.Since the extraction ratio of the active ingredient included in the raw material may be different depending on the polarity of the solvent, it may be different in consideration of the selectivity of the physiologically active material according to the solvent.
상기 추출물은 추출 원료를 물로 수세한 후 건조 및 분쇄하여, 원료 중량의 8 내지 12배에 달하는 부피의 용매로 약 1 내지 24시간 동안 환류 순환 추출, 가압 추출, 초음파 추출 등 통상적인 방법으로 추출 및 여과하여 제조할 수 있다.The extract is extracted by conventional methods such as reflux circulation extraction, pressure extraction, ultrasonic extraction, etc. for about 1 to 24 hours with a solvent in a volume equivalent to 8 to 12 times the weight of the raw material by washing the raw material for extraction with water and drying and pulverizing it It can be prepared by filtration.
상기 추출물은 감압 증류 또는 동결 건조 등과 같은 추가적인 공정에 의해 분말 상태로 수득할 수 있다.The extract may be obtained in a powder state by an additional process such as distillation under reduced pressure or freeze-drying.
상기 추출물은 통상적인 정제 과정을 거친 추출물도 포함할 수 있다. 예컨대, 상기 추출물은 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 분리, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획물을 포함할 수 있다.The extract may also include an extract that has undergone a conventional purification process. For example, the extract is separated using an ultrafiltration membrane having a constant molecular weight cut-off value, and various purification methods are additionally performed, such as separation by various chromatography (prepared for separation according to size, charge, hydrophobicity or affinity). It may include a fraction obtained through
본 발명의 다른 측면에 따르면, 동과 발효 추출물을 유효성분으로 포함하는 항산화용 식품 조성물이 제공된다.According to another aspect of the present invention, there is provided a food composition for antioxidant comprising copper and fermented extract as an active ingredient.
상기 “항산화”는 산화를 억제하는 작용을 의미하는 것으로, 인체는 산화촉 진물질과 산화억제물질이 균형을 이루고 있으나, 여러 가지 요인들로 인하여 이러한 균형 상태를 잃고 산화를 촉진하는 방향으로 기울게 되면, 생체 내에 산화적 스트레스(oxidative stress)가 유발되어 세포손상 및 병리적 질환을 유발할 수 있다.The “antioxidation” refers to the action of inhibiting oxidation, and the human body has a balance between an oxidation promoting substance and an oxidation inhibitory substance. , oxidative stress is induced in the living body, which may cause cell damage and pathological diseases.
산화적 스트레스의 직접적 원인이 되는 활성산소종(reactive oxygen species, ROS)은 화학적으로 불안정하고 반응성이 높아 DNA, 단백질, 지질 및 탄수화물과 같은 여러 생체물질과 쉽게 반응할 수 있으며, 생체 내 고분자들을 공격하여 세포와 조직에 비가역적인 손상을 일으키거나 돌연변이, 세포독성 및 암 등을 초래하게 되고, 노화의 직접적인 원인이 되기도 한다. Reactive oxygen species (ROS), a direct cause of oxidative stress, are chemically unstable and highly reactive, so they can easily react with various biological materials such as DNA, proteins, lipids and carbohydrates, and attack macromolecules in the living body. It causes irreversible damage to cells and tissues, mutation, cytotoxicity, cancer, etc., and is also a direct cause of aging.
따라서, 상기 활성산소종을 제거하거나 감소시킴으로써 항산화 효과를 얻어 노화를 방지하고 건강을 유지할 수 있다.Therefore, it is possible to prevent aging and maintain health by obtaining an antioxidant effect by removing or reducing the reactive oxygen species.
상기 식품 조성물은 환경호르몬 유발 활성산소종을 억제할 수 있다.The food composition can inhibit endocrine disruptor-induced reactive oxygen species.
상기 활성산소종(Reactive Oxygen Species, ROS)은 지방세포의 분화를 유도하거나 세포 주변 대식세포를 자극하기 때문에 당뇨와 같은 대사성 질환의 원인이 될 수 있으며, 상기 조성물은 활성산소종의 발생을 효과적으로 억제함으로써 환경호르몬에 의해 유발될 수 있는 대사증후군의 예방 또는 개선할 수 있다.Since the reactive oxygen species (ROS) induces differentiation of adipocytes or stimulates macrophages around cells, it may cause metabolic diseases such as diabetes, and the composition effectively inhibits the generation of reactive oxygen species. By doing so, it is possible to prevent or improve metabolic syndrome that can be caused by environmental hormones.
상기 식품 조성물은 환경호르몬 관련 질환, 예컨대 지질대사이상 개선을 위한 건강기능식품으로서 사용될 수 있다.The food composition may be used as a health functional food for endocrine disruptor related diseases, such as lipid metabolism improvement.
상기 건강기능식품은 건강기능식품에 관한 법률에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, 상기 기능성은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미할 수 있다.The health functional food means a food manufactured and processed using raw materials or ingredients useful for the human body in accordance with the Health Functional Food Act, and the functionality is to control nutrients or physiologically affect the structure and function of the human body. It may refer to ingestion for the purpose of obtaining useful effects for health purposes, such as action.
상기 식품 조성물은 통상의 식품 첨가물을 포함할 수 있으며, 상기 식품 첨가물은 다른 규정이 없는 한 식품의약품안전처에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 적합성 여부를 판단할 수 있다.The food composition may include normal food additives, and unless otherwise specified, the food additives are approved by the Ministry of Food and Drug Safety according to the general rules and general test methods of the Food Additives Code, according to the standards and standards for the item. suitability can be judged.
상기 식품 첨가물 공전에 기재된 품목은 예컨대 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성물, 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류를 들 수 있다.Items described in the Food Additives Codex include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; Mixtures, such as an added alkali agent, a preservative agent, and a tar dye agent, are mentioned.
상기 식품 조성물은 건강 개선을 위한 식품 및 음료 등에 다양하게 이용될 수 있으며, 예컨대, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강기능성 보조 식품, 식품 첨가제 등에 사용될 수 있다.The food composition can be used in various ways, such as food and beverage for health improvement, for example, can be used in various foods, beverages, gum, tea, vitamin complexes, health functional supplements, food additives, and the like.
또한, 상기 건강기능식품은 건강 개선을 목적으로 정제, 과립, 분말, 캅셀, 액상의 용액 및 환으로 이루어진 군에서 선택된 어느 하나의 제형으로 제조 및 가공될 수 있다.In addition, the health functional food may be manufactured and processed into any one formulation selected from the group consisting of tablets, granules, powders, capsules, liquid solutions and pills for the purpose of improving health.
구체적으로 상기 정제 형태의 건강기능식품은 동과 발효 추출물, 부형제, 결합제, 붕해제 및 다른 첨가제와의 혼합물을 통상의 방법으로 과립화한 후, 활택제 등을 넣어 압축 성형하거나, 상기 혼합물을 직접 압축 성형하여 제조할 수 있다. 또한, 상기 정제 형태의 건강기능식품은 필요에 따라 교미제 등을 함유할 수 있으며, 필요에 따라 적당한 제피제로 제피할 수도 있다.Specifically, the health functional food in the form of tablets is granulated with a mixture of copper and fermented extract, excipients, binders, disintegrants and other additives in a conventional manner, and then compression-molded by adding a lubricant or the like, or the mixture is directly processed It can be manufactured by compression molding. In addition, the health functional food in the form of tablets may contain a mating agent, etc., if necessary, and may be coated with a suitable skinning agent if necessary.
상기 캅셀 형태의 건강기능식품 중 경질캅셀제는 통상의 경질캅셀에 동과 발효 추출물 및 부형제 등의 첨가제와의 혼합물 또는 그의 입상물 또는 제피한 입상물을 충진하여 제조할 수 있으며, 연질캅셀제는 동과 발효 추출물 및 부형제 등의 첨가제와의 혼합물을 젤라틴 등 캅셀기제에 충진하여 제조할 수 있다. 상기 연질캅셀제는 필요에 따라 글리세린 또는 솔비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.Among the health functional foods in the form of capsules, hard capsules can be prepared by filling conventional hard capsules with a mixture of copper, fermented extract and additives such as excipients, or their granules or skinned granules. It can be prepared by filling a mixture with additives such as ferment extract and excipients in a capsule base such as gelatin. The soft capsules may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary.
상기 환 형태의 건강기능식품은 동과 발효 추출물, 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 적당한 제피제로 제피를, 또는 전분, 탈크 또는 적당한 물질로 환의를 입힐 수도 있다.The health functional food in the form of a ring can be prepared by molding a mixture of copper and fermented extract, excipients, binders, disintegrants, etc. in an appropriate way, and if necessary, the skin is coated with sucrose or other suitable skinning agent, or starch, talc, or You can also dress the gown with a suitable material.
상기 과립형태의 건강기능식품은 동과 발효 추출물, 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다. The health functional food in the form of granules can be prepared in a granular form by a suitable method of a mixture of copper and fermented extract, excipients, binders, disintegrants, and the like, and may contain flavoring agents, flavoring agents, etc. as necessary.
또한, 상기 부형제, 결합제, 붕해제, 활택제, 교미제, 착향제 등에 대한 용어 정의는 당업계에 공지된 문헌에 기재된 것으로 그 기능 등이 동일 내지 유사한 것들을 포함할 수 있다.In addition, the definitions of terms for the excipients, binders, disintegrants, lubricants, flavoring agents, and the like are described in documents known in the art and may include those having the same or similar functions.
본 발명의 다른 측면에 따르면, 동과 발효 추출물을 유효성분으로 포함하는 대사증후군의 예방 또는 치료용 약학적 조성물이 제공된다.According to another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating metabolic syndrome comprising a copper ferment extract as an active ingredient.
상기 “예방”은 병리학적 현상의 발생 빈도 또는 정도를 감소시키는 모든 행위를 의미한다. 예방은 완전할 수 있으며 또는 부분적일 수도 있다. 이 경우에는 개체 내의 대사 이상에 의해 발생되는 증상이 상기 조성물을 사용하지 않은 경우와 비교하여 감소하는 현상을 의미할 수 있다.The “prevention” refers to any action that reduces the frequency or extent of the occurrence of pathological phenomena. Prevention may be complete or partial. In this case, it may mean a phenomenon in which symptoms caused by metabolic abnormalities in the individual are reduced compared to the case where the composition is not used.
상기 “치료”는 치료하고자 하는 대상 또는 세포의 천연 과정을 변경시키기 위하여 임상적으로 개입하는 모든 행위를 의미하며, 임상 병리 상태가 진행되는 동안 또는 이를 예방하기 위하여 수행할 수 있다. The "treatment" refers to any action that clinically intervenes to change the natural process of a subject or cell to be treated, and may be performed while a clinical pathology is in progress or to prevent it.
목적하는 치료 효과는 질병의 발생 또는 재발을 예방하거나, 증상을 완화시키거나, 질병에 따른 모든 직접 또는 간접적인 병리학적 결과를 저하시키거나, 전이를 예방하거나, 질병 진행 속도를 감소시키거나, 질병 상태를 경감 또는 일시적 완화시키거나, 예후를 개선시키는 것을 포함할 수 있다.The desired therapeutic effect is to prevent the occurrence or recurrence of a disease, alleviate symptoms, reduce any direct or indirect pathological consequences of the disease, prevent metastasis, reduce the rate of disease progression, alleviating or temporarily ameliorating the condition, or improving the prognosis.
상기 조성물은 경구적 전달, 비경구적 전달의 형태로 투여될 수 있다. 상기 조성물은 전신 또는 국소 투여될 수 있으며, 상기 투여는 경구 투여 및 비경구 투여를 포함할 수 있다. 상기 조성물은 적절한 투여 형태를 제공하도록 적합한 양의 약학적으로 허용되는 비히클 또는 담체와 함께 제형화될 수 있다.The composition may be administered in the form of oral delivery or parenteral delivery. The composition may be administered systemically or locally, and the administration may include oral administration and parenteral administration. The compositions may be formulated with a suitable amount of a pharmaceutically acceptable vehicle or carrier to provide an appropriate dosage form.
상기 조성물은 약학 조성물의 제조에 사용되는 담체, 부형제 및 희석제를 더 포함할 수 있다. 상기 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 또는 광물유를 들 수 있으나, 이에 제한되는 것은 아니다.The composition may further include a carrier, excipient and diluent used in the preparation of the pharmaceutical composition. The carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil.
또한, 상기 조성물은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제제화하여 사용할 수 있다.In addition, the composition may be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions.
경구 투여를 위한 고형제제는 정제, 환제, 산제, 과립제, 캡슐제 등이 사용될 수 있고, 상기 고형제제는 상기 동과 발효 추출물과 이의 분획물들에 적어도 하나 이상의 부형제, 예컨대, 전분, 칼슘카보네이트, 수크로스, 락토오스, 또는 젤라틴 등을 혼합하여 조제할 수 있다. 또한, 상기 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제가 사용될 수 있다.A solid preparation for oral administration may include tablets, pills, powders, granules, capsules, etc., and the solid preparation includes at least one excipient in the copper and ferment extract and its fractions, for example, starch, calcium carbonate, water It can be prepared by mixing cross, lactose, or gelatin. In addition to the above excipients, lubricants such as magnesium stearate and talc may be used.
경구 투여를 위한 액상 제제는 현탁제, 내용액제, 유제, 시럽제 등이 사용될 수 있고, 단순희석제인 물, 리퀴드 파라핀 외에 여러 가지 부형제, 예컨대 습윤제, 감미제, 방향제, 보존제 등이 사용될 수 있다.Liquid formulations for oral administration may include suspensions, solutions, emulsions, syrups, etc., and various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. may be used in addition to simple diluents such as water and liquid paraffin.
비경구 투여를 위한 제제는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 사용될 수 있다. 상기 비수성용제, 현탁제는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르가 사용될 수 있다. 상기 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴이 사용될 수 있다.Formulations for parenteral administration may be used as sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations, and suppositories. The non-aqueous solvent and suspension agent may be propylene glycol, polyethylene glycol, vegetable oil such as olive oil, or injectable ester such as ethyl oleate. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin oil, and glycerogelatin may be used.
상기 약학적 조성물은 약제학적으로 유효한 양이 대상체에 투여될 수 있다. 상기 “약제학적으로 유효한 양”은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.The pharmaceutical composition may be administered to a subject in a pharmaceutically effective amount. The “pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is dependent on the patient's type, severity, drug activity, and drug Sensitivity, time of administration, route of administration and rate of excretion, duration of treatment, factors including concomitant drugs, and other factors well known in the medical field.
상기 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와 순차적으로 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 바람직하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Taking all of the above factors into consideration, it is preferable to administer an amount capable of obtaining the maximum effect with a minimum amount without side effects, which can be easily determined by those skilled in the art.
이하 실시예를 통해, 본 발명을 더욱 상술하나 하기 실시예에 의해 본 발명이 제한되지 아니함은 자명하다.Through the following examples, the present invention will be described in more detail, but it is obvious that the present invention is not limited by the following examples.
실시예 1 : 효모(Example 1: yeast ( Saccharomyces cerevisiaeSaccharomyces cerevisiae ) 발효 추출물(HR1901-FRm-SC-W)) Ferment Extract (HR1901-FRm-SC-W)
멸균한 생동아 분쇄물 100g에 Saccharomyces cerevisiae 종균 10%(10mL)를 접종하고 25℃에서 72시간 동안 발효를 진행하였다. Saccharomyces
12시간 간격으로 동아 발효물을 샘플링하여 5배의 물을 넣고 120℃에서 4 시간 동안 끓여 추출한 후 여과하였다. Dong-a fermented product was sampled every 12 hours, added 5 times of water, boiled at 120° C. for 4 hours, extracted, and filtered.
농축기로 10 내지 20 brix로 농축한 후 동결건조기를 이용하여 분말화하여 시료화 하였다.After concentrating to 10 to 20 brix with a concentrator, it was powdered and sampled using a freeze dryer.
실시예 2 : 효모(Example 2: Yeast ( Galactomyces geotrichumGalactomyces geotrichum ) 발효 추출물(HR1901-FRm-GG-W)) Ferment Extract (HR1901-FRm-GG-W)
멸균한 생동아 분쇄물 100g에 Galactomyces geotrichum 종균 10%(10mL)를 접종하고 25℃에서 72시간 동안 발효를 진행하였다. 10% (10 mL) of Galactomyces geotrichum spawn was inoculated into 100 g of sterilized raw chickpeas, and fermentation was performed at 25° C. for 72 hours.
12시간 간격으로 동아 발효물을 샘플링하여 5배의 물을 넣고 120℃에서 4 시간 동안 끓여 추출한 후 여과하였다. Dong-a fermented product was sampled every 12 hours, added 5 times of water, boiled at 120° C. for 4 hours, extracted, and filtered.
농축기로 10 내지 20 brix로 농축한 후 동결건조기를 이용하여 분말화하여 시료화 하였다.After concentrating to 10 to 20 brix with a concentrator, it was powdered and sampled using a freeze dryer.
실시예 3 : 간균(Example 3: Bacillus ( Bacillus subtilisBacillus subtilis ) 발효 추출물(HR1901-FRm-BS-W)) Ferment Extract (HR1901-FRm-BS-W)
멸균한 생동아 분쇄물 100g에 Bacillus subtilis 종균 10%(10mL)를 접종하고 25℃에서 72시간 동안 발효를 진행하였다. Bacillus
12시간 간격으로 동아 발효물을 샘플링하여 5배의 물을 넣고 120℃에서 4 시간 동안 끓여 추출한 후 여과하였다.Dong-a fermented product was sampled every 12 hours, added 5 times of water, boiled at 120° C. for 4 hours, extracted, and filtered.
농축기로 10 내지 20 brix로 농축한 후 동결건조기를 이용하여 분말화하여 시료화 하였다.After concentrating to 10 to 20 brix with a concentrator, it was powdered and sampled using a freeze dryer.
실시예 4 : 간균(Example 4: Bacillus ( Bacillus subtilis Bacillus subtilis CJH 101) 발효 추출물(HR1901-FRm-BS/1-W)CJH 101) Fermented Extract (HR1901-FRm-BS/1-W)
멸균한 생동아 분쇄물 미국 국립생물공학정보센터(NCBI)에 등록한 균주인 Bacillus subtilis CJH 101(등록번호 MW063656) 종균 10%(10mL)를 접종하고 25℃에서 72시간 동안 발효를 진행하였다. Bacillus subtilis CJH 101 (registration number MW063656), a strain registered with the National Center for Biotechnology Information (NCBI), 10% (10 mL) of the sterilized pulverized raw material, was inoculated, and fermentation was carried out at 25° C. for 72 hours.
12시간 간격으로 동아 발효물을 샘플링하여 5배의 물을 넣고 120℃에 4 시간 동안 끓여 추출한 후 여과하였다. Donga fermented product was sampled every 12 hours, added 5 times the amount of water, boiled at 120° C. for 4 hours, extracted and filtered.
농축기로 10 내지 20 brix로 농축한 후 동결건조기를 이용하여 분말화하여 시료화 하였다.After concentrating to 10 to 20 brix with a concentrator, it was powdered and sampled using a freeze dryer.
실시예 5 : 류코노스톡 균주(Example 5: Leukonostok strain ( Leuconostoc mesenterodiesLeuconostoc mesenterodies CJH 205) 발효 추출물(HR1901-FRm-LM/5-W) CJH 205) Fermented Extract (HR1901-FRm-LM/5-W)
멸균한 생동아 분쇄물 100g에 미국 국립생물공학정보센터(NCBI)에 등록한 균주인 Leuconostoc mesenterodies CJH 205(등록번호 MW079917) 종균 10%(10mL)를 접종하고 15℃에서 72시간 동안 발효를 진행하였다. 100 g of sterilized raw chickpeas were inoculated with 10% (10 mL) of Leuconostoc mesenterodies CJH 205 (registration number MW079917), a strain registered with the National Center for Biotechnology Information (NCBI), and fermented at 15°C for 72 hours.
12시간 간격으로 동아 발효물을 샘플링하여 5배의 물을 넣고 120℃에 4 시간 동안 끓여 추출한 후 여과하였다. Donga fermented product was sampled every 12 hours, added 5 times the amount of water, boiled at 120° C. for 4 hours, extracted and filtered.
농축기로 10 내지 20 brix로 농축한 후 동결건조기를 이용하여 분말화하여 시료화 하였다.After concentrating to 10 to 20 brix with a concentrator, it was powdered and sampled using a freeze dryer.
실험예 1 : 세포 배양Experimental Example 1: Cell Culture
세포주인 RAW264.7 macrophage cell은 American Type Culture Collection(ATCC, Manassas. USA)에서 구입하여 사용하였다.The cell line, RAW264.7 macrophage cell, was purchased from the American Type Culture Collection (ATCC, Manassas. USA).
세포의 배양을 위하여 10% Fetal Bovin Serum(FBS, Hyclone USA), 100 units/mL penicillin/Streptoycin(Hyclone, USA)이 함유된 DMEM(Dulbecco’s modified of Eagle’s medium, Hyclone, USA) 배지를 사용하였으며, 37℃, 5% CO2존재하의 incubator(Thermo, Forma, Germany)에서 배양하였다.For cell culture, DMEM (Dulbecco's modified of Eagle's medium, Hyclone, USA) medium containing 10% Fetal Bovin Serum (FBS, Hyclone USA) and 100 units/mL penicillin/Streptoycin (Hyclone, USA) was used, 37 C, and cultured in an incubator (Thermo, Forma, Germany) in the presence of 5% CO2.
실험예 2 : 독성 평가(MTT assay)Experimental Example 2: Toxicity evaluation (MTT assay)
살아있는 세포 내 미토콘드리아의 탈수소효소에 의해 Tetrazolium salt(WST-1)에서 formazan으로 변화하는 것을 이용하여, 생성된 formazan의 농도를 spectrophotometer로 측정함으로써 세포 생존률을 측정하였다.Cell viability was measured by measuring the concentration of the generated formazan with a spectrophotometer using a change from tetrazolium salt (WST-1) to formazan by mitochondrial dehydrogenase in living cells.
Ez-cytox(Dozen, Korea)을 이용하여 프로토콜에 따라 MTT assay를 수행하였다.MTT assay was performed according to the protocol using Ez-cytox (Dozen, Korea).
Raw264.7 세포를 5x103cells/100μL로 96 well에 분주한 후 37℃, 5% CO2 배양기에서 24시간 동안 배양하였다.Raw264.7 cells were aliquoted in 96 wells at 5x10 3 cells/100 μL, and then cultured at 37° C., 5% CO 2 in an incubator for 24 hours.
농도별로 시료를 처리한 후 24시간 동안 배양하였다. 배양 후 10% MTT 시약이 포함된 배지로 교체하고 37℃에서 1시간 동안 반응시킨 후 450nm 파장에서 microplate reader(Epoch, Biotek)로 측정하였다.Samples were treated for each concentration and then cultured for 24 hours. After incubation, the medium containing 10% MTT reagent was replaced and reacted at 37° C. for 1 hour, followed by measurement with a microplate reader (Epoch, Biotek) at 450 nm wavelength.
각 시료에 대한 세포생존율에 의한 독성 평가는 3회 반복하여 측정하였으며, 그에 대한 평균값과 표준편차를 산출하였다.Toxicity evaluation by cell viability for each sample was repeated three times, and the average value and standard deviation thereof were calculated.
도 1을 참조하면, 동과 발효 추출물(실시예 1 내지 5)은 모든 발효 시간(12, 24, 48, 60, 72h) 및 농도(10, 100, 1000 μg/mL) 범위에서 세포 독성이 나타나지 않았다.1, the copper ferment extract (Examples 1 to 5) showed no cytotoxicity at all fermentation times (12, 24, 48, 60, 72h) and concentration (10, 100, 1000 μg/mL) ranges. didn't
실험예 3 : 환경호르몬에 의한 지질축적 유도 효과 확인Experimental Example 3: Confirmation of lipid accumulation induction effect by environmental hormones
환경호르몬에 의해 유도된 지질축적 확인을 위하여 환경호르몬으로 유도된 3T3-L1 지방세포 분화유도조건을 설정하였다.In order to confirm the lipid accumulation induced by environmental hormones, 3T3-L1 adipocyte differentiation inducing conditions induced by environmental hormones were set.
일반적으로 3T3-L1 지방세포를 분화시키기 위해 칵테일(methylisobutylxanthine, dexamethasone, insulin; MDI)을 사용할 수 있다.In general, a cocktail (methylisobutylxanthine, dexamethasone, insulin; MDI) can be used to differentiate 3T3-L1 adipocytes.
본 실험에서 MDI칵테일 및 비스페놀 A를 동시에 처리하였을 때, MDI에 의한 지질축적으로 인해 비스페놀 A의 지질축적을 확인할 수 없어 전지방세포에서 6일 간 비스페놀 A에 노출시킨 뒤 dexamethasone을 제외한 칵테일과 분화시켜 실험하였다.In this experiment, when MDI cocktail and bisphenol A were simultaneously treated, lipid accumulation of bisphenol A could not be confirmed due to lipid accumulation by MDI. Preadipocytes were exposed to bisphenol A for 6 days and then differentiated from cocktails except dexamethasone. experimented.
분화는 8일 동안 진행되었으며, MDI 처리군과 대비한 결과값을 산출하였다.Differentiation was performed for 8 days, and results compared to the MDI-treated group were calculated.
환경호르몬의 3T3-L1 세포 분화 및 지질축적 유도를 확인하기 위하여 중성지방만을 적색으로 염색하는 Oil Red O 염색법을 통해 3T3-L1 지방세포 내 생성된 중성지방의 양을 측정하였다.To confirm the 3T3-L1 cell differentiation and lipid accumulation induction of endocrine disruptors, the amount of triglycerides produced in 3T3-L1 adipocytes was measured through the Oil Red O staining method, which stains only triglycerides in red.
실험은 다양한 농도의 비스페놀 A, 비스페놀 S 및 비스페놀 F를 지방세포 분화 전 전지방세포에서 6일간 처리하였으며, 분화시 MI 칵테일과 함께 처리하여 환경호르몬으로 유도된 지질축적을 확인하였다.In the experiment, various concentrations of bisphenol A, bisphenol S and bisphenol F were treated in preadipocytes for 6 days before adipocyte differentiation, and lipid accumulation induced by environmental hormones was confirmed by treatment with MI cocktail during differentiation.
결과값은 MDI칵테일로 분화를 유도한 군과 비교하여 나타내었다.The results were compared with the group induced by MDI cocktail.
측정 결과 처리한 모든 농도에서 농도 유의적으로 지질축적이 MI 칵테일 처리군보다 증가하였다. As a result of the measurement, lipid accumulation was significantly increased in all concentrations treated than in the MI cocktail treatment group.
비스페놀 A의 대체제인 비스페놀 S 및 비스페놀 F에서도 지질축적이 증가하였다.Bisphenol S and bisphenol F, which are substitutes for bisphenol A, also increased lipid accumulation.
실험예 4 : 환경호르몬 유도 지질축적 억제능 평가Experimental Example 4: Evaluation of environmental hormone-induced lipid accumulation inhibitory ability
일반적으로 3T3-L1 지방세포를 분화시키기 위해 hormonal 칵테일 MDI(Dexamethasone, IBMX, Insulin)를 사용한다.In general, the hormonal cocktail MDI (Dexamethasone, IBMX, Insulin) is used to differentiate 3T3-L1 adipocytes.
본 실험에서 환경호르몬의 비만 유발(obesogenic) 효과를 확인하기 위해 전지방세포를 24-well plate에 10 x 106의 농도로 seeding하고, 분화 전 6일 동안 비스페놀 A(20 μM)를 처리하였다.In this experiment, to confirm the obesogenic effect of environmental hormones, whole adipocytes were seeded in a 24-well plate at a concentration of 10 x 106 and treated with bisphenol A (20 μM) for 6 days before differentiation.
세포가 밀집(confluent) 상태가 되면 MDI 처리군에는 1 μM dexamethasone, 0.5 mM 3-Isobutyl-1-methylxanthine(IBMX), 1 μg/mL insulin을 첨가해 분화를 유도하였으며, 그 외에는 dexamethasone을 제외한 IBMX 및 insulin을 처리하였다. When the cells became confluent, 1 μM dexamethasone, 0.5 mM 3-Isobutyl-1-methylxanthine (IBMX), and 1 μg/mL insulin were added to the MDI-treated group to induce differentiation. Insulin was treated.
또한 MI 처리군을 제외한 후 20 μM 환경호르몬을 처리하였으며, 5 mM NAC 및 200 μg/mL의 시료를 DMSO에 녹여 분화 10일 동안 처리하고 효능을 평가하였다.In addition, after excluding the MI treatment group, 20 μM endocrine disruptor was treated, and a sample of 5 mM NAC and 200 μg/mL was dissolved in DMSO, treated for 10 days of differentiation, and efficacy was evaluated.
분화 과정에 따른 지방세포 내 지방 축적량을 측정하고자 각각의 시료를 처리하여 10일 동안 분화된 3T3-L1 세포에 10% 포르말린(formalin) 용액 500 μL를 첨가하여 5분간 실온에서 방치한 후 제거하였다. To measure the amount of fat accumulation in adipocytes according to the differentiation process, 500 μL of a 10% formalin solution was added to 3T3-L1 cells differentiated for 10 days after processing each sample, leaving it at room temperature for 5 minutes, and then removing it.
동량의 포르말린 용액으로 분화된 3T3-L1 세포 1시간 이상 실온에서 방치하여 plate에 고정시켰다. 3T3-L1 cells differentiated with the same amount of formalin solution were left at room temperature for at least 1 hour and fixed on a plate.
60% 아이소프로판올(isopropanol) 용액 500 μL로 세척하여 세포를 완전히 건조시킨 후, 미리 제조해 둔 Oil Red O working solution(ORO : DDW=6:4)으로 세포 내 축적된 지방성분들을 충분히 염색하였다.After washing with 500 μL of a 60% isopropanol solution and drying the cells completely, the fat components accumulated in the cells were sufficiently stained with the Oil Red O working solution (ORO: DDW=6:4) prepared in advance.
증류수를 이용하여 세포를 3 내지 4회 세척하고, 세포 내 축적된 지방 성분과 결합한 ORO는 100% 아이소프로판올을 이용하여 모두 용출시킨 후 microplate reader를 이용하여 490 nm에서 흡광도를 측정하였다(표 1).Cells were washed 3 to 4 times using distilled water, and all OROs combined with fat components accumulated in the cells were eluted using 100% isopropanol, and then absorbance was measured at 490 nm using a microplate reader (Table 1). .
처리군treatment group
처리군treatment group
처리군treatment group
표 1 및 도 2를 참조하면, 동과 발효 추출물 소재는 환경호르몬에 의해 축적되는 지질의 양을 농도 의존적으로 감소시켰다Referring to Table 1 and Figure 2, the copper and fermented extract material reduced the amount of lipids accumulated by environmental hormones in a concentration-dependent manner.
100 μg/mL 동과 발효 추출물에서는 항산화 및 항비만 활성이 있는 것으로 알려진 5 mM n-acetylcysteine(NAC)과 유사한 수준으로 나타났다.In 100 μg/mL copper ferment extract, it was found at a level similar to 5 mM n-acetylcysteine (NAC), which is known to have antioxidant and anti-obesity activities.
실험예 5 : 환경호르몬 유도 ROS 생성 억제능 평가Experimental Example 5: Evaluation of environmental hormone-induced ROS production inhibitory ability
분화 과정에 따른 지방세포 내 ROS 생성량을 측정하고자 각각의 시료를 처리하여 10일 동안 분화된 3T3-L1 세포에 PBS를 이용하여 2회 세척하였다.To measure the amount of ROS production in adipocytes according to the differentiation process, each sample was treated and the differentiated 3T3-L1 cells were washed twice with PBS for 10 days.
0.2% NBT 용액 200 μL를 첨가하여 CO2incubator에서 90분간 반응시킨 후 DMSO 및 1N KOH 7:3 혼합 용액으로 dark blue formazan을 용출시켰다. After adding 200 μL of 0.2% NBT solution and reacting in a CO2 incubator for 90 minutes, dark blue formazan was eluted with a mixed solution of DMSO and 1N KOH 7:3.
용출물은 microplate reader를 이용하여 490 nm에서 흡광도를 측정하였다.The absorbance of the eluate was measured at 490 nm using a microplate reader.
처리군treatment group
처리군treatment group
처리군treatment group
표 2 및 도 3을 참조하면, NBT(nitroblue tetrazoliu)와 ROS가 반응하여 형성된 dark blue formazan의 흡광도를 측정한 결과 환경호르몬은 지방세포의 분화시 활성산소의 생성을 유도하였으며, H2-DCFDA 형광염색을 통해 ROS를 측정한 결과 환경호르몬 처리로 인해 형광도가 증가하였다.Referring to Table 2 and Figure 3, the absorbance of dark blue formazan formed by the reaction of NBT (nitroblue tetrazoliu) and ROS was measured. As a result, the environmental hormone induced the generation of active oxygen during adipocyte differentiation, and H2-DCFDA fluorescent staining. As a result of measuring ROS through endocrine disruptor, the fluorescence intensity was increased due to endocrine disruptor treatment.
반면, 동과 발효 추출물을 처리한 실험군에서 환경호르몬에 의해 유발된 ROS의 생성이 효과적으로 억제되었다. On the other hand, in the experimental group treated with the copper ferment extract, the generation of ROS induced by environmental hormones was effectively suppressed.
상기 결과는 동과 발효 추출물이 항산화 활성이 우수할 뿐만 아니라, 환경호르몬에 의해 유발될 수 있는 생체 내 이상지질대사를 효과적으로 완화시킬 수 있음을 시사한다.The above results suggest that the fermented copper extract not only has excellent antioxidant activity, but can also effectively alleviate abnormal lipid metabolism in vivo that may be induced by environmental hormones.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예를 들어, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다.The description of the present invention described above is for illustration, and those of ordinary skill in the art to which the present invention pertains can understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. For example, each component described as a single type may be implemented in a dispersed form, and likewise components described as distributed may also be implemented in a combined form.
본 발명의 범위는 후술하는 청구범위에 의하여 나타내어지며, 청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the present invention is indicated by the following claims, and all changes or modifications derived from the meaning and scope of the claims and their equivalents should be construed as being included in the scope of the present invention.
Claims (8)
상기 대사증후군은 환경호르몬 유발 지질대사이상인, 식품 조성물.The method of claim 1,
The metabolic syndrome is an environmental hormone-induced lipid metabolism abnormality, a food composition.
상기 환경호르몬은 비스페놀류, 파라벤류, 또는 프탈레이트류인, 식품 조성물.3. The method of claim 2,
The environmental hormone is bisphenols, parabens, or phthalates, the food composition.
상기 동과 발효 추출물은 사카로마이세스 속(Saccharomyces spp.), 갈락토마이세스 속(Galactomyces spp.), 바실러스 속(bacillus spp.), 및 류코노스톡 속(Leuconostoc spp.)으로 이루어진 군에서 하나 이상 선택된 균주를 발효시켜 수득한 것인, 식품 조성물.The method of claim 1,
The copper ferment extract is from the group consisting of Saccharomyces spp. , Galactomyces spp. , Bacillus spp. , and Leuconostoc spp. A food composition obtained by fermenting one or more selected strains.
상기 바실러스 속 균주는 바실러스 메가테리(Bacillus megaterium), 바실러스 아밀로리퀴페시언스(Bacillus amyloliquefaciens), 바실러스 서브틸리스(Bacillus subtilis)로 이루어진 군에서 하나 이상 선택된, 식품 조성물.5. The method of claim 4,
The Bacillus sp. strain is Bacillus megaterium ( Bacillus megaterium ), Bacillus amyloliquefaciens ( Bacillus amyloliquefaciens ), Bacillus subtilis ( Bacillus subtilis ) One or more selected from the group consisting of, food composition.
상기 바실러스 속 균주는 미국 국립생물공학정보센터(NCBI)에 등록된 Bacillus subtilis CJH 101(MW063656) 이고,
상기 류코노스톡 속 균주는 미국 국립생물공학정보센터에 등록된 Leuconostoc mesenterodies CJH 205(MW079917)인, 식품 조성물.5. The method of claim 4,
The Bacillus sp. strain is Bacillus subtilis CJH 101 (MW063656) registered with the US National Center for Biotechnology Information (NCBI),
The Leuconostoc sp. strain is Leuconostoc mesenterodies CJH 205 (MW079917) registered with the US National Center for Biotechnology Information, a food composition.
상기 대사증후군은 환경호르몬 유발 지질대사이상인, 약학적 조성물.8. The method of claim 7,
The metabolic syndrome is an environmental hormone-induced lipid metabolism abnormality, a pharmaceutical composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200138474A KR20220054025A (en) | 2020-10-23 | 2020-10-23 | A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising fermented-benicasa hispida extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200138474A KR20220054025A (en) | 2020-10-23 | 2020-10-23 | A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising fermented-benicasa hispida extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220054025A true KR20220054025A (en) | 2022-05-02 |
Family
ID=81593201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200138474A KR20220054025A (en) | 2020-10-23 | 2020-10-23 | A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising fermented-benicasa hispida extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20220054025A (en) |
-
2020
- 2020-10-23 KR KR1020200138474A patent/KR20220054025A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101851195B1 (en) | Fermented mulberry leaves, femented mulberry leaves extract and use there of | |
| KR101425486B1 (en) | Extract of Smilax china leaf with Aspergillus species, method for preparing the same and use of the same | |
| KR20160007728A (en) | Method for manufacturing garlic skin extract and food composition for preventing and alleviating diabetes prepared using the same | |
| EP2650005A2 (en) | Composition comprising fermented tea extracts for reducing lipid level | |
| KR20210098225A (en) | A composition for diabetes or cardiovascular disease treatment comprising a citrus fermented kombucha | |
| KR20170100977A (en) | Antioxidant composition comprising fermented extract of ilex paraguayensis, houttuynia cordata, illicium verum and undaria pinnatifida and manufacturing method thereof | |
| CN109069562A (en) | Polysaccharide digests inhibitor | |
| JP6778026B2 (en) | Whitening agents and whitening foods and drinks containing 4'-demethylnobiletin as an active ingredient | |
| KR101226824B1 (en) | A composition comprising the extract of Sorghum bicolor L. Moench as an active ingredient for preventing and treating inflammatory disease | |
| KR102501955B1 (en) | A composition for immune enhancement comprising benicasa hispida extract | |
| JP2007131599A (en) | Plant extract containing glycation-inhibiting ability and method for producing the same | |
| JP2007131599A6 (en) | Plant extract having glycation-inhibiting ability and method for producing the same | |
| KR20220054025A (en) | A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising fermented-benicasa hispida extract | |
| KR102472951B1 (en) | A composition for immune enhancement comprising narrow-leaf erecta fig extract mixture | |
| JP2006182706A (en) | Agent for increasing adiponectin amount in blood | |
| KR101608502B1 (en) | Composition for prevention or treatment of cardiovascular diseases comprising fermentation product of garlic | |
| KR102499105B1 (en) | A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising narrow-leaf erecta fig extract | |
| KR20220054024A (en) | A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising benicasa hispida extract | |
| KR101385191B1 (en) | Use of Cichorium intybus extracts for preventing, treating improving muscular atrophy | |
| KR101219683B1 (en) | Composition with tyrosinase inhibition activity of grain Koji fermented with Aspergillus oryzae and Astragali Radix and method thereof | |
| KR100895500B1 (en) | Composition for the prevention and treatment of fatty liver diseases containing honokiol as an active ingredient | |
| KR101798205B1 (en) | Food composition increased gamma-aminobutyric acid comprising fermentated barley leaf and corn silk as active ingredient | |
| KR20200000743A (en) | A composition for improving diabetes or for use of antioxidant comprising yeast extract and a method for preparing the yeast extract | |
| KR102619375B1 (en) | A composition for improving, preventing and treating of obesity comprising Centella asiatica fermentation extract | |
| KR101370679B1 (en) | Method for manufacturing solid-state fermented Allium victorialis and Composition for preventing or treating anti-diabetes or anti-diabetic complication containing fermented Allium victorialis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |